Revolutionary breast-KI: Early cancer early detection by Transpara!

Revolutionary breast-KI: Early cancer early detection by Transpara!

Laimgrubengasse 10, 1060 Wien, Österreich - At the 110th annual conference of the Radiological Society of North America (RSNA) in Chicago, Screenpoint Medical presented a groundbreaking FDA approval for its leading Breast AI system Transpara on December 3, 2024. This system is considered the best validated breast AI on the market and offers radiologists a "second pair of eyes" to recognize breast cancer earlier and reduce the recall rates, as the company announced in a message. Transpara 2.1, the latest update, includes improved algorithms based on further training and knowledge of experts, and is compatible with both Birads and volumetric options and a time comparison function. This unique function enables suspicious areas in a recent study with up to three older recordings over a period of up to six years.

"The consideration of tissue changes to the characterization of findings is a long -awaited function of the AI," explained Professor Nico Karssemeijer, co -founder and Chief Scientific Officer from ScreenPoint Medical. The improvements of the algorithm are based on extensive, real studies in large population groups, which were carried out at UCLA as well as on Danish and Swedish institutions. With Transpara, up to 45 % of interval carcinomas can be discovered earlier, while the workload of the radiologists is lowered, numerous scientific studies confirmed during the RSNA. Biospace reported that the implementation of the Transpara technology in the clinical processes shows.

additional studies and results